navitoclax and Pancreatic-Neoplasms

navitoclax has been researched along with Pancreatic-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for navitoclax and Pancreatic-Neoplasms

Article	Year
Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax. Bioorganic & medicinal chemistry letters, 2021, 07-01, Volume: 43 Cyclin-dependent kinase 9 (CDK9) is a member of the cyclin-dependent kinase (CDK) family which is involved in transcriptional regulation of several genes, including the oncogene Myc, and is a validated target for pancreatic cancer. Here we report the development of an aminopyrazole based proteolysis targeting chimera (PROTAC 2) that selectively degrades CDK9 (DC Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Cyclin-Dependent Kinase 9; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proteolysis; Pyrazoles; Structure-Activity Relationship; Sulfonamides	2021

Article

Year

Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.

Bioorganic & medicinal chemistry letters, 2021, 07-01, Volume: 43

Cyclin-dependent kinase 9 (CDK9) is a member of the cyclin-dependent kinase (CDK) family which is involved in transcriptional regulation of several genes, including the oncogene Myc, and is a validated target for pancreatic cancer. Here we report the development of an aminopyrazole based proteolysis targeting chimera (PROTAC 2) that selectively degrades CDK9 (DC

Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Cyclin-Dependent Kinase 9; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proteolysis; Pyrazoles; Structure-Activity Relationship; Sulfonamides

2021